lansoprazole has been researched along with Pharyngitis in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Pharyngitis: Inflammation of the throat (PHARYNX).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 6.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes." | 5.17 | Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. ( Blake, KB; Gong, Y; Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wise, RA, 2013) |
| "Persistent throat symptoms and Extra Oesophageal Reflux (EOR) are among the commonest reasons for attendance at a secondary care throat or voice clinic." | 2.82 | TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. ( Carding, P; Fouweather, T; Lecouturier, J; O'Hara, J; Stocken, D; Watson, G; Wilson, J, 2016) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 2.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saul, H | 1 |
| Gursul, D | 1 |
| Kwint, J | 1 |
| O'Hara, J | 3 |
| Stocken, DD | 1 |
| Watson, GC | 1 |
| Fouweather, T | 2 |
| McGlashan, J | 1 |
| MacKenzie, K | 1 |
| Carding, P | 2 |
| Karagama, Y | 1 |
| Wood, R | 1 |
| Wilson, JA | 1 |
| Lima, JJ | 1 |
| Lang, JE | 1 |
| Mougey, EB | 1 |
| Blake, KB | 1 |
| Gong, Y | 1 |
| Holbrook, JT | 1 |
| Wise, RA | 1 |
| Teague, WG | 1 |
| Watson, G | 1 |
| Lecouturier, J | 1 |
| Stocken, D | 1 |
| Wilson, J | 1 |
| Hatlebakk, JG | 1 |
| Nesje, LB | 1 |
| Hausken, T | 1 |
| Bang, CJ | 1 |
| Berstad, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013] | Phase 4 | 306 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24
| Intervention | mg/mL (Mean) |
|---|---|
| Lansoprazole Group | 2.6 |
| Placebo Group | 2.5 |
ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 0.86 |
| Placebo Group | 0.88 |
Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 5.8 |
| Placebo Group | 6.0 |
Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 1.1 |
| Placebo Group | 1.0 |
A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | Liters (Mean) |
|---|---|
| Lansoprazole Group | 2.2 |
| Placebo Group | 2.3 |
"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary
| Intervention | number of episodes of poor asthma contrl (Number) |
|---|---|
| Lansoprazole Group | 230 |
| Placebo Group | 184 |
4 trials available for lansoprazole and Pharyngitis
| Article | Year |
|---|---|
Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesophageal R | 2021 |
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Asthma; Bronchit | 2013 |
TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial.
Topics: Clinical Protocols; Feasibility Studies; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngophary | 2016 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsu | 1995 |
1 other study available for lansoprazole and Pharyngitis
| Article | Year |
|---|---|
Proton pump inhibitors should not be used to treat persistent throat symptoms.
Topics: Cough; Humans; Lansoprazole; Pharyngitis; Practice Patterns, Physicians'; Proton Pump Inhibitors | 2022 |